Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Novo Nordisk
Pen is first insulin injection device combining half-unit dosing and memory function
PLAINSBORO, N.J., Jan. 21, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo® in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.
"We are excited to make NovoPen Echo® available in the United States for patients and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately," said George McAvoy, vice president, NovoLog® brand team at Novo Nordisk.
Half-unit dose increments allow for finer adjustments, which can be particularly important for children. In addition, 12 fun removable skins are available for a customized look, including kid-friendly designs.
"Children with type 1 diabetes have unique needs in regards to diabetes management," said Children with Diabetes founder Jeff Hitchcock. "It is so important that new, innovative tools continue to be developed so that children and caregivers have options. NovoPen Echo®, which features half-unit dosing from the start and memory function, is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home."
This pen is the latest insulin delivery system offered from Novo Nordisk, and is available to patients for use with NovoLog® PenFill® cartridges.
Novo Nordisk has already launched NovoPen Echo® in Europe, Canada, and Israel. For more information on Novo Nordisk products, please visit www.novonordisk-us.com.
Please see Important Safety Information below.
Indications and Usage
What is NovoLog® (insulin aspart [rDNA origin] injection)?
Important Safety Information
Who should not use NovoLog®?
What should I tell my health care provider before taking NovoLog®?
How should I take NovoLog®?
What should I consider while using NovoLog®?
What are the possible side effects of NovoLog® (insulin aspart [rDNA origin] injection)?
Please visit novolog.com for Prescribing Information.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global health care company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk-us.com or follow our news in the US on Twitter: @NovoNordiskUS.
In the United States, 25.8 million people have diabetes,1 a condition in which the body does not produce enough or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life.
NovoPen Echo®, NovoLog®, and PenFill® are registered trademarks of Novo Nordisk A/S.
© 2014 Novo Nordisk All rights reserved. 1213-00019488-1 January 2014
1 2011 National Diabetes Fact Sheet. Centers for Disease Control. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed December 11, 2013.
©2012 PR Newswire. All Rights Reserved.
1720 Valley View Drive